PT  - JOURNAL ARTICLE
AU  - Allison Meisner
AU  - Prosenjit Kundu
AU  - Yan Dora Zhang
AU  - Lauren V. Lan
AU  - Sungwon Kim
AU  - Disha Ghandwani
AU  - Parichoy Pal Choudhury
AU  - Sonja I. Berndt
AU  - Neal D. Freedman
AU  - Montserrat Garcia-Closas
AU  - Nilanjan Chatterjee
TI  - Combined Utility of 25 Disease and Risk Factor Polygenic Risk Scores for Stratifying Risk of All-Cause Mortality
AID  - 10.1101/2020.03.13.20035527
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.13.20035527
4099  - http://medrxiv.org/content/early/2020/06/16/2020.03.13.20035527.short
4100  - http://medrxiv.org/content/early/2020/06/16/2020.03.13.20035527.full
AB  - While genome-wide association studies have identified susceptibility variants for numerous traits, their combined utility for predicting broad measures of health, such as mortality, remains poorly understood. We used data from the UK Biobank to combine polygenic risk scores (PRS) for 13 diseases and 12 mortality risk factors into sex-specific composite PRS (cPRS). These cPRS were moderately associated with all-cause mortality in independent data: the estimated hazard ratios per standard deviation were 1.10 (95% confidence interval: 1.05, 1.16) and 1.15 (1.10, 1.19) for women and men, respectively. Differences in life expectancy between the top and bottom 5% of the cPRS were estimated to be 4.79 (1.76, 7.81) years and 6.75 (4.16, 9.35) years for women and men, respectively. These associations were substantially attenuated after adjusting for non-genetic mortality risk factors measured at study entry. The cPRS may be useful in counseling younger individuals at higher genetic risk of mortality on modification of non-genetic factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Patient-Centered Outcomes Research Institute (grant number ME-1602-34530); the National Institutes of Health (1 R01 HG010480-01); and the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used are available from the UK Biobank upon request. https://www.ukbiobank.ac.uk